Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adelphi Real World Metastatic Urothelial Cancer Disease Specific Programme: Study of Real-world Data to Evaluate Patient Characteristics, Treatment Pattern and Healthcare Resource Utilisation of Locally Advanced or Metastatic Urothelial Cancer (La/mUC) at First-line Setting Post Avelumab Reimbursement in South Korea and Saudi Arabia

NCT06505746 is registered in ClinicalTrials.gov with Astellas Pharma Singapore Pte. Ltd. as lead sponsor.

NCT NCT06505746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06505746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adelphi Real World Metastatic Urothelial Cancer Disease Specific Programme: Study of Real-world Data to Evaluate Patient Characteristics, Treatment Pattern and Healthcare Resource Utilisation of Locally Advanced or Metastatic Urothelial Cancer (La/mUC) at First-line Setting Post Avelumab Reimbursement in South Korea and Saudi Arabia
Lead sponsor
Astellas Pharma Singapore Pte. Ltd.
Phase
Observational
Overall status
Completed
Start date
August 29, 2024
Completion date
January 31, 2025
Enrollment
287 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial cancer